• BioNxt secured patent protection in Europe and Eurasia for its core cladribine sublingual thin-film drug delivery technology.
• The company’s corresponding U.S. patent application remains under USPTO Track One prioritized examination.
• Management framed the patent grants as a foundation for clinical development, commercial partnerships, licensing discussions for its cladribine multiple sclerosis program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNxt Solutions Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608040305ACCESSWRNAPR_____1201146) on August 04, 2026, and is solely responsible for the information contained therein.